Guarini Kathryn sold $360K of REGN

Guarini Kathryn sold 400 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $900.00 ($0.36M total) on 2026-10-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Guarini Kathryn
Published Nov 3, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REGN
Bearish
medium confidence
Mentioned
$REGN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNBearishLow
01

Why it matters

The disclosed sale is modest relative to Regeneron's market cap and likely will not move the stock significantly.

02

Market read

A routine insider sale with limited market impact; traders may note the transaction but no immediate action is required.

03

What to watch

The 10b5-1 plan indicates the sale was pre‑planned, reducing the informational value of the transaction.

Relevance 3/10Novelty 3/10Timing: post‑market today

Background

SEC Form 4 filing discloses insider transactions; directors often use 10b5-1 plans to execute pre‑arranged trades.

Company-level read

Ticker impact

$REGNBearishMedium confidence
Context

Director Kathryn Guarini sold 400 shares of Regeneron for $360,000 via a 10b5-1 plan, reducing her stake to 603 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

A director sold a modest amount of stock under a pre‑arranged plan; such sales typically signal neutral to mildly negative sentiment.

Market effects

Minimal impact on the biotech sector; insider sales are routine.

No significant regional effect.

Limited to Regeneron investors.

Counterpoint

The sale could be unrelated to company fundamentals and may be purely portfolio rebalancing.

Key entities

  • Regeneron Pharmaceuticals, Inc.

    Biopharmaceutical company whose director sold shares.

  • Kathryn Guarini

    Director of Regeneron who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REGNMed

These patients struggle with runaway bones. Finally there’s hope

The FDA approved two new treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Regeneron's garetosmab (Pasatru) and Mirum's zilurgisertib (Atebrioz) reduce abnormal bone growth. FOP affects about 900 people worldwide, with limited mobility and shortened lifespans. Trials for pediatric use are ongoing.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.